Company intelligence / Profile preview
Alumis Inc.
South San Francisco, California, United Statesx.com ↗
- Ownership
- Public · ALMS
- Development stage
- Phase 3
01
Overview
Alumis’ lead candidate ESK‑001 has shown strong symptomatic improvement in moderate-to-severe plaque psoriasis. It is currently being evaluated in a pivotal Phase 3 trial for this indication with topline data expected first half of 2026. The company’s second asset, A‑005, completed a successful Phase 1 trial and will enter a multiple sclerosis study. Several preclinical programs are also advancing using their precision analytics platform.[6]
- Therapeutic areas
- NeurologyImmunologyDermatology
- Modalities
- Small molecules (oral TYK2 inhibitors)Allosteric inhibitors
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Merger with ACELYRIN to form a late-stage immunology biopharma leader.[1][3]
04
Financials
- Market cap
- $1.2B
- Total revenue
- $1.7M
- Enterprise value
- $743.8M
Beyond the preview
Go deeper on Alumis Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alumis Inc..